Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Feb 28, 2008

AstraZeneca RECENTIN BR24 Non-Small Cell Lung Cancer Trial Will Not Progress

27 February 2008 - ... AstraZeneca also announced that the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) has informed AstraZeneca that the BR24 Phase II/III study of RECENTIN at 30mg in first line non-small cell lung cancer (NSCLC) will not continue into Phase III following the planned end of Phase II efficacy and tolerability analysis by the study’s Data Safety Monitoring Committee. Although evidence of clinical activity was seen, there appeared to be an imbalance in toxicity and therefore the study was considered not to have met the pre-defined criteria for automatic continuation into Phase III... AstraZeneca's Press Release -